TECKRO
29.9.2021 15:06:05 CEST | Business Wire | Press release
Teckro, the creator of the only clinical trials platform that facilitates collaboration and real-time decision-making between and among stakeholders, announces new product capabilities to accelerate site adoption of modern trial practices, making communication even easier at the point of care. A next-generation mobile app gives investigators and site staff answers in fewer clicks, while platform enhancements will result in new studies operational on Teckro in half the time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005472/en/
Toward its vision of engaging every physician in clinical research, Teckro also unveils its “Teckro Powered” site program to establish a community of research sites ready to advance the industry and help shape future product requirements. Today, more than 23,000 research sites around the world rely on the Teckro platform for clinical trials in all therapeutic areas.
“With a critical mass of sites using Teckro, we deepen our commitment to a simple, site-driven experience that allows physicians to easily engage in research without compromising time caring for patients,” says Teckro CEO Gary Hughes. “Sponsors can ease the complexity of clinical trials with a frictionless way to communicate with sites, including when investigators can receive direct guidance from study experts at the point of care.”
First-Of-Its-Kind Site Program: Teckro Powered
“Teckro Powered” is a novel program open to any research site. The program includes a dedicated sandbox to preview Teckro capabilities and input into future requirements. In addition with the program, sites and site networks can:
- Build a technology-ready brand. Teckro Powered sites are technically savvy. Designated with a program badge on their websites and social media platforms, sites can use this to differentiate themselves and build their reputations as “sites of choice” for sponsors.
- Expand physician participation in research. Behind the Teckro Powered program is a community of research sites to open a new way to collaborate and advance the industry. With the strength of a Teckro Powered community, the goal is to encourage more physicians to participate in clinical trials, reaching broader, diverse patient populations.
- Limit impact of staff turnover. Teckro Powered is a way for sites to mitigate disruption from staff turnover. With study resources conveniently hosted in Teckro and accessible from a smartphone, sites can simplify new study member onboarding. A central source for content, communication and collaboration reduces the time to train new staff over the course of a trial.
“The Teckro Powered program fills a gap in the industry,” says Director of Site Strategy Silvina Baudino. “Working with sites for almost 20 years, I know how challenging clinical research can be. Teckro is dedicated to the site experience, which you see in both the new product capabilities and the investment in the Teckro Powered program. We are creating a way for sites to differentiate themselves and participate in a community of research sites.”
Maximizing Sponsor-Site Collaboration
Teckro’s latest platform enhancements go toward solving gaps in communication and easing the burden on site staff. A hub for study content and communication, the new Teckro capabilities include:
- Next-generation mobile application. The streamlined app provides a simple, mobile-first user experience to support point of care decisions. Based on deep user research, the new mobile application is optimally designed for clinical trial answers in just a couple of clicks. The new Teckro mobile app is now available in the app stores for Apple and Android smartphones.
- Diverse experts on demand . Teckro is expanding its communication to support more granular groups of experts for different types of site queries. Real-time guidance from those best suited to provide answers eliminates the need for a “switchboard” or for study monitors to operate as a go-between. The feature will be available in the fourth quarter.
- Increased speed and scale. Underlying platform improvements mean new studies can be added in half the time. This allows sponsors to standardize on Teckro as a resource for their sites to access current study content and communications across trials.
Meet Teckro at the Global Site Solution Summit
Teckro is a sponsor at the upcoming Global Site Solution Summit (October 1-3). Visit us at Booth 716 to see a demo and talk with our experts. You can also request a meeting with Silvina Baudino (Teckro director of site strategy) or Malia Lewin (Teckro global head of strategy) by completing the form on our event page
. Silvina will also participate as a panelist in the breakout session “It's Not You, It's Me: How to Manage Long-Term Partnerships” on both October 2 at 1:30 p.m. and October 3 at 9 a.m.
About Teckro
Recognized as one of the fastest growing clinical trial start-ups, Teckro transforms the study protocol into a hub of communication and collaboration. It’s a digital platform that connects all study stakeholders with the knowledge they need, when they need it. Thousands of investigators and more than 23,000 sites around the world rely on Teckro to execute clinical trials from biopharma sponsors, including 12 out of the Top 20 pharma companies. Teckro supports all therapeutic areas, all phases, and any trial format ranging from traditional in-clinic, decentralized clinical trials, or a hybrid approach.
More Information
- Visit teckro.com
- Connect with Teckro on LinkedIn
- Follow @teckroofficial on Twitter and Instagram
- Like Teckro on Facebook
- Subscribe to the Teckro YouTube channel
- Named as one of Linkedin’s official top ten Irish startups 2021
- Featured on Sifted’s Irish startups to watch list 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20210929005472/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons opens office in Warsaw as Polish applications reach 50,000 in 202621.9.2026 09:15:00 CEST | Press release
Bending Spoons has opened an office in Warsaw, adding to its Milan headquarters and locations in London and Madrid. The technology company, whose portfolio includes Eventbrite and WeTransfer, has seen a sharp rise in applications from Poland and will use the new base to recruit locally for roles across key projects. “We’ve received around 50,000 applications from Poland so far this year, more than twice as many as the whole of 2025. What stands out isn’t just the volume. Many Polish candidates are among the strongest we see in our selection process, and the student talent has been particularly impressive. More than half of our recent hires from Poland were still studying when they applied,” says Andrea Maiorana, Talent data lead. Located in Śródmieście, Warsaw’s city center, the office is within walking distance of the Presidential Palace and the University of Warsaw. Bending Spoons encourages all new hires to spend their first few months in Milan, with travel and accommodation costs f
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
